Additionally, this study demonstrates that treatment of human ACC cells with OSI-906, a dual IGF1R/IR inhibitor, reduces cell proliferation and that combined treatment with linsitinib and mTOR inhibitors can have additive antiproliferative effects. Here, MTOR is linked to adrenal cortex carcinoma.